MB 106

Drug Profile

MB 106

Alternative Names: MB-106; MB-106 CD20 CAR - Mustang Bio

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; Mustang Bio
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Oct 2017 UMass Medicine Science Park and Mustang bio entered into an agreement to support the clinical development and commercialisation of CAR T therapies
  • 01 Oct 2017 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (Parenteral)
  • 14 Sep 2017 Mustang Bio plans a phase I/II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater) in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top